73 Interestingly, 7 R/R patients received the triplet ENA+AZA+Ven and showed a trend toward a better mOS than those treated with ENA+AZA. 73 Preliminary results of a phase Ib/II clinical trial (Enaven-AML trial) explored enasidenib in combination with VEN in a group of AML patients previously treated with at least two lines of treatment and mostly with relapsing or refractory disease. 74 A CR rate of 55% was observed, and all responders remained in remission during the study. 74 Since IDH mutations induced inhibition of the TET2 enzyme, it seemed interesting to explore the effect of VEN-based therapies in TET2 -mutated AMLs.
← all excerpts
The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.
1
—
—